| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c4419ee35316f3d43ad7a207b103cbe9 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 |
| filingDate |
2019-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01b2d6fa10d4b56c81e444c567cfb0a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7eae3db915a5aea7e070f10d8bdf24ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_052a43f8f7e8a8006aabf94e0cb621ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8832388ee8e2a6eee67eda2ad685bbc7 |
| publicationDate |
2020-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-110846402-A |
| titleOfInvention |
Application of hsa-circ-0004287 as a therapeutic target in the preparation of drugs for the treatment of atopic dermatitis |
| abstract |
The invention discloses the application of hsa‑circ‑0004287 as a therapeutic target in preparing a medicine for treating atopic dermatitis. In the present invention, peripheral blood mononuclear cells of patients with atopic dermatitis and normal people are collected, and circRNA chip analysis is performed, and hsa‑circ‑0004287 is screened out to be significantly highly expressed in patients with atopic dermatitis. In THP1 cells, hsa‑circ‑0004287 exerted a certain anti-inflammatory effect by significantly reducing the phosphorylation level of p38 protein and then inhibiting the expression of downstream inflammatory mediators induced by LPS. Our study showed that hsa‑circ‑0004287 was significantly overexpressed in atopic dermatitis patients, and it significantly inhibited LPS-induced inflammation caused by M1 polarization of macrophages, suggesting that hsa‑circ‑0004287 may act as a function of atopic dermatitis A new target for intervention therapy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114736962-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114736962-B |
| priorityDate |
2019-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |